Company profile
Cannonau Corp.
OTC: CNNC · Healthcare · Drug Manufacturers - Specialty & Generic
#1160 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 12GM —SS 33
v0.1 · 25/100 weight · pillars only
↑ net margin, listing tenure · ↓ Altman-Z, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$338.2k
Employees
4
as of 2026-08-28
Market cap
$48.3k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$227$2272022
Net income$338.2k$338.2k2023
Operating income-$24.4k-$24.4k2023
Total assets$0$02023
Equity-$338.2k-$338.2k2022
Revenue trend
FY2020 – FY2022 · USD
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cannonau Corp.’s revenue?
Cannonau Corp. booked $227 in FY2022 revenue, contracting 96% year over year — among the slowest-growing Healthcare companies we track, at a 149002.6% net margin.
Peers · Healthcare
Health Discovery Corporation——ProText Mobility, Inc.——That Marketing Solution, Inc.——Ludwig Enterprises, Inc.12DItonis, Inc.25DGlobeStar Therapeutics Corporation——Neighbors
Onondaga →Key facts
CEOMarkwin Maring
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSkaneateles, NY
ExchangeOTC: CNNC
Employees4
IPO date2010-03-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.